Therapeutic Drug Monitoring Market by Product (Consumables, Equipment-Immunoassay Analyzers, Chromatography & MS Detectors, Clinical Chemistry Analyzers), Technology, Class of drugs, End user and Region - Global Forecast to 2027
The global therapeutic drug monitoring market is projected to reach USD 2.9 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 9.6% during the forecast period. The growth of this market is majorly driven by a high awaiting number of organ transplant procedures and the expanding inclination for precision medicine. However, a lack of infrastructure and low awareness in middle/low-income countries may challenge the growth of this market.
“Liquid Chromatography-Mass Spectrometry in the technology segment to witness the highest growth during the forecast period.”
Based on the technology, the Therapeutic Drug Monitoring Market is segmented into Immunoassays - Chemiluminescence Immunoassays, Chemiluminescence Immunoassays, Colorimetric Immunoassays, Fluorescence Immunoassays, Radioimmunoassay, Other Immunoassays, Chromatography-MS - LC-MS, GC-MS, The LC-MS is projected to grow at the highest CAGR during the forecast period. The significant factors contributing to the growth of this market are affordability, reliability, and its availability in automated platform, as well as wide benefits of advanced HPLC usage in TDM drugs.
“Asia Pacific is estimated to register the highest CAGR during the forecast period.”
In this report, the Therapeutic Drug Monitoring market is segmented into four major regional segments: North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market in Asia Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is primarily driven by the upsurging population (especially in Japan and China), availaibility of comprehensive government healthcare coverage in Japan (for transplantation & related diagnostic procedures), government efforts to increase awareness about primitive disease detection and health check-ups, rising government expenditure in China and India to remodel and expand healthcare infrastructure, and the growing prevalence of severe diseases
Breakdown of supply-side primary interviews, by company type, designation, and region:
This report studies the Therapeutic Drug Monitoring market based on product and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total Therapeutic Drug Monitoring market. The report forecasts the revenue of the market segments with respect to five major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
“Liquid Chromatography-Mass Spectrometry in the technology segment to witness the highest growth during the forecast period.”
Based on the technology, the Therapeutic Drug Monitoring Market is segmented into Immunoassays - Chemiluminescence Immunoassays, Chemiluminescence Immunoassays, Colorimetric Immunoassays, Fluorescence Immunoassays, Radioimmunoassay, Other Immunoassays, Chromatography-MS - LC-MS, GC-MS, The LC-MS is projected to grow at the highest CAGR during the forecast period. The significant factors contributing to the growth of this market are affordability, reliability, and its availability in automated platform, as well as wide benefits of advanced HPLC usage in TDM drugs.
“Asia Pacific is estimated to register the highest CAGR during the forecast period.”
In this report, the Therapeutic Drug Monitoring market is segmented into four major regional segments: North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market in Asia Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is primarily driven by the upsurging population (especially in Japan and China), availaibility of comprehensive government healthcare coverage in Japan (for transplantation & related diagnostic procedures), government efforts to increase awareness about primitive disease detection and health check-ups, rising government expenditure in China and India to remodel and expand healthcare infrastructure, and the growing prevalence of severe diseases
Breakdown of supply-side primary interviews, by company type, designation, and region:
- By Company Type: Tier 1 (32%) , Tier 2 (44%), and Tier 3 (24%)
- By Designation: C-level (30%), Director-level (34%), and Others (36%)
- By Region: North America (40%), Europe (28%), AsiaPacific (20%), and Rest of the World(12%)
- Abbott (US)
- Thermo Fisher Scientific (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Siemens Healthineers AG (Germany)
- Danaher Corporation (US)
- Bio-Rad Laboratories (US)
- bioM?rieux SA (France)
- Theradiag SA (France)
- Grifols S.A. (Spain)
- Exagen Inc. (US)
- R-Biopharm AG (Germany)
- ARK DIAGNOSTICS, Inc. (US)
- Cambridge Life Sciences Limited (UK)
- B?HLMANN Laboratories (Switzerland)
- IMMUNDIAGNOSTIK AG (Germany)
- BioTeZ Berlin-Buch GmbH (Germany)
- UTAK (US)
- DiaSystem Scandinavia AB (Sweden)
- Jasem Laboratory Systems and Solutions (Turkey)
- Aalto Scientific, Ltd. (US)
- apDia Group (Belgium)
- SJK Global, LLC. (US)
- Epitope Diagnostics, Inc. (US)
- Sekisui Medical Co. Ltd. (Japan)
- Eagle Biosciences, Inc. (US)
- Chromsystems Instruments & Chemicals GmbH (Germany)
This report studies the Therapeutic Drug Monitoring market based on product and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total Therapeutic Drug Monitoring market. The report forecasts the revenue of the market segments with respect to five major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on Therapeutic Drug Monitoring products offered by the top 26 players in the therapeutic drug monitoring market. The report analyzes the therapeutic drug monitoring market by product, and region.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.
- Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the Therapeutic Drug Monitoring market
- Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the Therapeutic Drug Monitoring market
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
TABLE 1 KEY DATA FROM PRIMARY SOURCES
FIGURE 3 KEY INDUSTRY INSIGHTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
FIGURE 7 APPROACH 3: MARKET SIZE ESTIMATION FROM PARENT MARKET
2.2.1.1 Growth forecast
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 9 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS
2.6 RISK ASSESSMENT
2.7 IMPACT OF RECESSION
3 EXECUTIVE SUMMARY
FIGURE 11 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 12 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 13 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022 VS. 2027 (USD MILLION)
FIGURE 14 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 15 GEOGRAPHIC ANALYSIS: THERAPEUTIC DRUG MONITORING MARKET
4 PREMIUM INSIGHTS
4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW
FIGURE 16 RISING PREFERENCE FOR PRECISION MEDICINE TO DRIVE TDM MARKET
4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY AND DRUG CLASS
FIGURE 17 ANTIEPILEPTIC DRUGS ACCOUNTED FOR LARGEST SHARE IN 2021
4.3 THERAPEUTIC DRUG MONITORING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 18 CHINA TO REGISTER HIGHEST CAGR
4.4 THERAPEUTIC DRUG MONITORING MARKET, BY REGION (2022–2027)
FIGURE 19 ASIA PACIFIC MARKET TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.5 THERAPEUTIC DRUG MONITORING MARKET: DEVELOPED VS. EMERGING ECONOMIES
FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Importance of TDM in organ transplant procedures
FIGURE 22 UK: NUMBER OF DECEASED DONORS AND TRANSPLANTS (APRIL 1, 2017–MARCH 31, 2021)
5.2.1.2 Use of TDM across various therapeutic fields
TABLE 2 CLASSES OF DRUGS THAT REQUIRE MONITORING
5.2.1.3 Increasing preference for precision medicine
FIGURE 23 PERSONALIZED MEDICINE APPROVALS BY US FDA, 2015–2021
5.2.1.4 Growing focus on R&D related to TDM
FIGURE 24 NUMBER OF RESEARCH PUBLICATIONS ON TDM (2015–2021)
5.2.1.5 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
FIGURE 25 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
TABLE 3 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
5.2.2 RESTRAINTS
5.2.2.1 High capital investments
5.2.2.2 Reluctance of small hospitals to offer TDM services
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing prevalence of autoimmune diseases
5.2.3.2 Significant opportunities in BRICS countries
FIGURE 26 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2012–2019
5.2.4 CHALLENGES
5.2.4.1 Alternatives to conventional TDM
5.2.4.2 Operational barriers faced in conducting TDM tests
5.2.4.3 Lack of infrastructure and low awareness in low/middle-income countries
5.3 TECHNOLOGY ANALYSIS
5.4 VALUE CHAIN ANALYSIS
FIGURE 27 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 28 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.6 PORTER’S FIVE FORCES ANALYSIS
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 INTENSITY OF COMPETITIVE RIVALRY
5.6.3 BARGAINING POWER OF BUYERS
5.6.4 BARGAINING POWER OF SUPPLIERS
5.6.5 THREAT OF SUBSTITUTES
5.7 KEY STAKEHOLDERS AND BUYING CRITERIA
5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS
TABLE 4 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%)
5.7.2 BUYING CRITERIA
FIGURE 30 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 5 KEY BUYING CRITERIA FOR TOP THREE END USERS
5.8 REGULATORY LANDSCAPE
TABLE 6 REGULATORY AUTHORITIES GOVERNING TDM MARKET
5.9 KEY CONFERENCES AND EVENTS IN 2022 AND 2023
TABLE 7 LIST OF CONFERENCES AND EVENTS, 2022–2023
5.10 PATENT ANALYSIS
FIGURE 31 PATENT ANALYSIS FOR IMMUNOASSAY ANALYZERS
FIGURE 32 PATENT ANALYSIS FOR CLINICAL CHEMISTRY ANALYZERS
5.11 PRICING ANALYSIS
TABLE 8 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (2022)
TABLE 9 PRICE RANGE FOR THERAPEUTIC DRUG MONITORING PRODUCTS
5.12 TRADE ANALYSIS
TABLE 10 IMPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2016–2021 (USD MILLION)
TABLE 11 EXPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2016–2021 (USD MILLION)
5.13 ECOSYSTEM ANALYSIS
TABLE 12 ROLE IN ECOSYSTEM
FIGURE 33 KEY MARKET PLAYERS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
FIGURE 34 REVENUE SHIFT FOR THERAPEUTIC DRUG MONITORING
6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 13 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 CONSUMABLES
6.2.1 REPEAT PURCHASES AND HIGH USAGE OF CONSUMABLES TO DRIVE MARKET
TABLE 14 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 EQUIPMENT
TABLE 15 DRUGS MONITORED USING ANALYTICAL EQUIPMENT
TABLE 16 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 17 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.1 IMMUNOASSAY ANALYZERS
6.3.1.1 High efficiency of immunoassay analyzers to ensure end-user demand
TABLE 18 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2020–2027 (USD MILLION)
6.3.2 CHROMATOGRAPHY & MS DETECTORS
6.3.2.1 Technological advancements to propel growth
TABLE 19 CHROMATOGRAPHY & MS DETECTORS: PRODUCT LAUNCHES, BY COMPANY (2020 TO 2021)
TABLE 20 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2020–2027 (USD MILLION)
6.3.3 CLINICAL CHEMISTRY ANALYZERS
6.3.3.1 Automation to raise preference for clinical chemistry analyzers
TABLE 21 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2020–2027 (USD MILLION)
7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 22 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
7.2 IMMUNOASSAYS
TABLE 23 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 24 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.1 CHEMILUMINESCENCE IMMUNOASSAYS
7.2.1.1 Rapid detection time and good specificity to support growth
TABLE 25 CLIA SYSTEMS OFFERED, BY COMPANY
TABLE 26 LIST OF COMPOUNDS ANALYZED BY CHEMILUMINESCENCE IMMUNOASSAYS
TABLE 27 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.2 FLUORESCENCE IMMUNOASSAYS
7.2.2.1 High operability and better sensitivity of FIAs to drive market growth
TABLE 28 LIST OF COMPOUNDS ANALYZED BY FLUORESCENCE POLARIZATION IMMUNOASSAYS
TABLE 29 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.3 COLORIMETRIC IMMUNOASSAYS
7.2.3.1 Demand for colorimetric immunoassays to decline due to rising preference for advanced equipment
TABLE 30 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.4 RADIOIMMUNOASSAYS
7.2.4.1 High sensitivity in drug detection applications to support market growth
TABLE 31 LIST OF COMPOUNDS ANALYZED BY RADIOIMMUNOASSAYS
TABLE 32 RADIOIMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.5 OTHER IMMUNOASSAYS
TABLE 33 OTHER IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3 CHROMATOGRAPHY-MS
TABLE 34 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
7.3.1.1 High accuracy to drive demand for LC-MS
TABLE 35 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
7.3.2.1 Drawbacks of GC-MS to challenge market growth
TABLE 36 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2020–2027 (USD MILLION)
8 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS
8.1 INTRODUCTION
TABLE 37 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
8.2 ANTIEPILEPTIC DRUGS
8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE GROWTH
TABLE 38 TDM: LIMITATIONS FACED IN NEW ANTIEPILEPTIC DRUGS
TABLE 39 ANTIEPILEPTIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
8.3 ANTIARRHYTHMIC DRUGS
8.3.1 INCREASING INCIDENCE OF HEART DISORDERS TO BOOST DEMAND
TABLE 40 ANTIARRHYTHMIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
8.4 IMMUNOSUPPRESSANT DRUGS
8.4.1 RISING IMMUNOSUPPRESSANT DEMAND DRIVEN BY INCREASE IN ORGAN TRANSPLANTATION PROCEDURES
FIGURE 35 PATIENTS ON WAITING LIST VS. TRANSPLANTS PERFORMED, BY ORGAN, 2021
TABLE 41 IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
8.5 ANTIBIOTIC DRUGS
8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL DEMAND FOR ANTIBIOTIC DRUG MONITORING
TABLE 42 COMPARISON OF DIFFERENT TECHNOLOGIES FOR DETERMINING ANTIMICROBIALS LEVELS IN BIOFLUIDS
TABLE 43 ANTIBIOTIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
8.6 BRONCHODILATOR DRUGS
8.6.1 RISING PREVALENCE OF RESPIRATORY DISEASES TO ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING
TABLE 44 BRONCHODILATOR DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
8.7 PSYCHOACTIVE DRUGS
8.7.1 SURGING CASES OF MENTAL ILLNESS TO AUGMENT MARKET GROWTH
TABLE 45 PSYCHOACTIVE DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
8.8 OTHER DRUGS
TABLE 46 OTHER DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
9 THERAPEUTIC DRUG MONITORING MARKET, BY END USER
9.1 INTRODUCTION
TABLE 47 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 HOSPITAL LABORATORIES
9.2.1 HOSPITAL LABS TO DOMINATE END-USER MARKET
TABLE 48 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
9.3 COMMERCIAL & PRIVATE LABORATORIES
9.3.1 EXTENSIVE TEST MENUS OF COMMERCIAL & PRIVATE LABS TO SUSTAIN DEMAND FOR SERVICES
TABLE 49 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
9.4 OTHER END USERS
TABLE 50 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
10 THERAPEUTIC DRUG MONITORING MARKET, BY REGION
10.1 INTRODUCTION
TABLE 51 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 36 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
TABLE 52 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 54 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 55 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 56 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 57 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 58 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 59 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.2 US
10.2.2.1 Awareness regarding precision medicine to propel market
TABLE 60 NUMBER OF TESTS COVERED BY MEDICARE FOR EACH DRUG CLASS
TABLE 61 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 62 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 63 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 64 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 65 US: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 66 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Availability of funding for research to offer growth opportunities
TABLE 67 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 68 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 69 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 70 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 71 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 72 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3 EUROPE
10.3.1 EUROPE: RECESSION IMPACT
TABLE 73 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 74 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 75 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 77 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 78 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 79 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 80 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Prevalence of chronic medical conditions such as cancer and diabetes to support market growth
TABLE 81 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 82 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 83 GERMANY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 84 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 85 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 86 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.3 ITALY
10.3.3.1 Rising incidence of cancer to drive demand for TDM
TABLE 87 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
TABLE 88 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 89 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 90 ITALY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 91 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 92 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 93 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Rising awareness of benefits of TDM to accelerate demand
TABLE 94 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 95 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 96 FRANCE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 98 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 99 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Adoption of technologically advanced immunoassays to boost market
TABLE 100 SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
TABLE 101 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 102 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 103 SPAIN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 104 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 105 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 106 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.6 UK
10.3.6.1 Increasing cases of chronic diseases to support market
TABLE 107 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 108 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 109 UK: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 110 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 111 UK: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 112 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 113 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 114 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 115 ROE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 116 ROE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 117 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 118 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 37 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
TABLE 119 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 120 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 121 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 123 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 124 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY- MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 125 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 126 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Japan to dominate APAC market
TABLE 127 JAPAN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
TABLE 128 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 129 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 130 JAPAN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 131 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 132 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 133 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Rising number of organ transplants to boost market
TABLE 134 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 135 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 136 CHINA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 138 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 139 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Rising incidence of cancer to propel market
TABLE 140 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 141 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 142 INDIA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 143 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 144 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 145 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.5 ROAPAC
TABLE 146 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 147 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 148 ROAPAC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 149 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 150 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 151 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.5 REST OF THE WORLD
10.5.1 ROW: RECESSION IMPACT
TABLE 152 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 153 ROW: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 154 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 155 ROW: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 156 ROW: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 157 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 158 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 159 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
11.3 REVENUE SHARE ANALYSIS
FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS
11.4 MARKET SHARE ANALYSIS
TABLE 160 THERAPEUTIC DRUG MONITORING MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 39 COMPANY EVALUATION QUADRANT: THERAPEUTIC DRUG MONITORING MARKET, 2021
11.6 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 40 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: THERAPEUTIC DRUG MONITORING MARKET, 2021
11.7 COMPANY FOOTPRINT ANALYSIS
TABLE 161 COMPANY FOOTPRINT
TABLE 162 COMPANY REGIONAL FOOTPRINT
TABLE 163 COMPANY PRODUCT FOOTPRINT
11.8 THERAPEUTIC DRUG MONITORING MARKET: DETAILED LIST OF KEY START-UPS/SMES
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 164 KEY PRODUCT LAUNCHES & APPROVALS
11.9.2 DEALS
TABLE 165 KEY DEALS
11.9.3 OTHER DEVELOPMENTS
TABLE 166 KEY OTHER DEVELOPMENTS
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 ABBOTT
TABLE 167 ABBOTT: BUSINESS OVERVIEW
FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2021)
12.1.2 THERMO FISHER SCIENTIFIC
TABLE 168 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 42 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
12.1.3 F. HOFFMANN-LA ROCHE
TABLE 169 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
FIGURE 43 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021)
12.1.4 SIEMENS HEALTHINEERS AG
TABLE 170 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 44 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
12.1.5 DANAHER CORPORATION
TABLE 171 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
12.1.6 BIO-RAD LABORATORIES
TABLE 172 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
FIGURE 46 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.7 BIOM?RIEUX SA
TABLE 173 BIOM?RIEUX SA: BUSINESS OVERVIEW
FIGURE 47 BIOM?RIEUX: COMPANY SNAPSHOT (2021)
12.1.8 THERADIAG
TABLE 174 THERADIAG: BUSINESS OVERVIEW
FIGURE 48 THERADIAG: COMPANY SNAPSHOT (2021)
12.1.9 GRIFOLS S.A.
TABLE 175 GRIFOLS S.A.: BUSINESS OVERVIEW
FIGURE 49 GRIFOLS S.A.: COMPANY SNAPSHOT (2021)
12.1.10 EXAGEN INC.
TABLE 176 EXAGEN INC.: BUSINESS OVERVIEW
FIGURE 50 EXAGEN INC.: COMPANY SNAPSHOT (2021)
12.1.11 ARK DIAGNOSTICS, INC.
TABLE 177 ARK DIAGNOSTICS, INC.: BUSINESS OVERVIEW
12.1.12 R-BIOPHARM AG
TABLE 178 R-BIOPHARM AG: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 APDIA GROUP
12.2.2 BIOTEZ BERLIN BUCH GMBH
12.2.3 EAGLE BIOSCIENCES, INC.
12.2.4 JASEM LABORATORY SYSTEMS AND SOLUTIONS
12.2.5 AALTO SCIENTIFIC, LTD.
12.2.6 IMMUNDIAGNOSTIK AG
12.2.7 UTAK
12.2.8 SEKISUI MEDICAL CO., LTD.
12.2.9 DIASYSTEM SCANDINAVIA AB
12.2.10 CAMBRIDGE LIFE SCIENCES LIMITED
12.2.11 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH
12.2.12 B?HLMANN LABORATORIES AG
12.2.13 SJK GLOBAL, LLC.
12.2.14 EPITOPE DIAGNOSTICS, INC.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 INSIGHTS FROM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 CUSTOMIZATION OPTIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
TABLE 1 KEY DATA FROM PRIMARY SOURCES
FIGURE 3 KEY INDUSTRY INSIGHTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
FIGURE 7 APPROACH 3: MARKET SIZE ESTIMATION FROM PARENT MARKET
2.2.1.1 Growth forecast
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 9 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS
2.6 RISK ASSESSMENT
2.7 IMPACT OF RECESSION
3 EXECUTIVE SUMMARY
FIGURE 11 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 12 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 13 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022 VS. 2027 (USD MILLION)
FIGURE 14 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 15 GEOGRAPHIC ANALYSIS: THERAPEUTIC DRUG MONITORING MARKET
4 PREMIUM INSIGHTS
4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW
FIGURE 16 RISING PREFERENCE FOR PRECISION MEDICINE TO DRIVE TDM MARKET
4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY AND DRUG CLASS
FIGURE 17 ANTIEPILEPTIC DRUGS ACCOUNTED FOR LARGEST SHARE IN 2021
4.3 THERAPEUTIC DRUG MONITORING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 18 CHINA TO REGISTER HIGHEST CAGR
4.4 THERAPEUTIC DRUG MONITORING MARKET, BY REGION (2022–2027)
FIGURE 19 ASIA PACIFIC MARKET TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.5 THERAPEUTIC DRUG MONITORING MARKET: DEVELOPED VS. EMERGING ECONOMIES
FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Importance of TDM in organ transplant procedures
FIGURE 22 UK: NUMBER OF DECEASED DONORS AND TRANSPLANTS (APRIL 1, 2017–MARCH 31, 2021)
5.2.1.2 Use of TDM across various therapeutic fields
TABLE 2 CLASSES OF DRUGS THAT REQUIRE MONITORING
5.2.1.3 Increasing preference for precision medicine
FIGURE 23 PERSONALIZED MEDICINE APPROVALS BY US FDA, 2015–2021
5.2.1.4 Growing focus on R&D related to TDM
FIGURE 24 NUMBER OF RESEARCH PUBLICATIONS ON TDM (2015–2021)
5.2.1.5 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
FIGURE 25 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
TABLE 3 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
5.2.2 RESTRAINTS
5.2.2.1 High capital investments
5.2.2.2 Reluctance of small hospitals to offer TDM services
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing prevalence of autoimmune diseases
5.2.3.2 Significant opportunities in BRICS countries
FIGURE 26 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2012–2019
5.2.4 CHALLENGES
5.2.4.1 Alternatives to conventional TDM
5.2.4.2 Operational barriers faced in conducting TDM tests
5.2.4.3 Lack of infrastructure and low awareness in low/middle-income countries
5.3 TECHNOLOGY ANALYSIS
5.4 VALUE CHAIN ANALYSIS
FIGURE 27 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 28 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.6 PORTER’S FIVE FORCES ANALYSIS
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 INTENSITY OF COMPETITIVE RIVALRY
5.6.3 BARGAINING POWER OF BUYERS
5.6.4 BARGAINING POWER OF SUPPLIERS
5.6.5 THREAT OF SUBSTITUTES
5.7 KEY STAKEHOLDERS AND BUYING CRITERIA
5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS
TABLE 4 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%)
5.7.2 BUYING CRITERIA
FIGURE 30 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 5 KEY BUYING CRITERIA FOR TOP THREE END USERS
5.8 REGULATORY LANDSCAPE
TABLE 6 REGULATORY AUTHORITIES GOVERNING TDM MARKET
5.9 KEY CONFERENCES AND EVENTS IN 2022 AND 2023
TABLE 7 LIST OF CONFERENCES AND EVENTS, 2022–2023
5.10 PATENT ANALYSIS
FIGURE 31 PATENT ANALYSIS FOR IMMUNOASSAY ANALYZERS
FIGURE 32 PATENT ANALYSIS FOR CLINICAL CHEMISTRY ANALYZERS
5.11 PRICING ANALYSIS
TABLE 8 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (2022)
TABLE 9 PRICE RANGE FOR THERAPEUTIC DRUG MONITORING PRODUCTS
5.12 TRADE ANALYSIS
TABLE 10 IMPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2016–2021 (USD MILLION)
TABLE 11 EXPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2016–2021 (USD MILLION)
5.13 ECOSYSTEM ANALYSIS
TABLE 12 ROLE IN ECOSYSTEM
FIGURE 33 KEY MARKET PLAYERS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
FIGURE 34 REVENUE SHIFT FOR THERAPEUTIC DRUG MONITORING
6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 13 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 CONSUMABLES
6.2.1 REPEAT PURCHASES AND HIGH USAGE OF CONSUMABLES TO DRIVE MARKET
TABLE 14 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 EQUIPMENT
TABLE 15 DRUGS MONITORED USING ANALYTICAL EQUIPMENT
TABLE 16 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 17 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.1 IMMUNOASSAY ANALYZERS
6.3.1.1 High efficiency of immunoassay analyzers to ensure end-user demand
TABLE 18 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2020–2027 (USD MILLION)
6.3.2 CHROMATOGRAPHY & MS DETECTORS
6.3.2.1 Technological advancements to propel growth
TABLE 19 CHROMATOGRAPHY & MS DETECTORS: PRODUCT LAUNCHES, BY COMPANY (2020 TO 2021)
TABLE 20 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2020–2027 (USD MILLION)
6.3.3 CLINICAL CHEMISTRY ANALYZERS
6.3.3.1 Automation to raise preference for clinical chemistry analyzers
TABLE 21 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2020–2027 (USD MILLION)
7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 22 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
7.2 IMMUNOASSAYS
TABLE 23 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 24 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.1 CHEMILUMINESCENCE IMMUNOASSAYS
7.2.1.1 Rapid detection time and good specificity to support growth
TABLE 25 CLIA SYSTEMS OFFERED, BY COMPANY
TABLE 26 LIST OF COMPOUNDS ANALYZED BY CHEMILUMINESCENCE IMMUNOASSAYS
TABLE 27 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.2 FLUORESCENCE IMMUNOASSAYS
7.2.2.1 High operability and better sensitivity of FIAs to drive market growth
TABLE 28 LIST OF COMPOUNDS ANALYZED BY FLUORESCENCE POLARIZATION IMMUNOASSAYS
TABLE 29 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.3 COLORIMETRIC IMMUNOASSAYS
7.2.3.1 Demand for colorimetric immunoassays to decline due to rising preference for advanced equipment
TABLE 30 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.4 RADIOIMMUNOASSAYS
7.2.4.1 High sensitivity in drug detection applications to support market growth
TABLE 31 LIST OF COMPOUNDS ANALYZED BY RADIOIMMUNOASSAYS
TABLE 32 RADIOIMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.5 OTHER IMMUNOASSAYS
TABLE 33 OTHER IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3 CHROMATOGRAPHY-MS
TABLE 34 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
7.3.1.1 High accuracy to drive demand for LC-MS
TABLE 35 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
7.3.2.1 Drawbacks of GC-MS to challenge market growth
TABLE 36 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2020–2027 (USD MILLION)
8 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS
8.1 INTRODUCTION
TABLE 37 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
8.2 ANTIEPILEPTIC DRUGS
8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE GROWTH
TABLE 38 TDM: LIMITATIONS FACED IN NEW ANTIEPILEPTIC DRUGS
TABLE 39 ANTIEPILEPTIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
8.3 ANTIARRHYTHMIC DRUGS
8.3.1 INCREASING INCIDENCE OF HEART DISORDERS TO BOOST DEMAND
TABLE 40 ANTIARRHYTHMIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
8.4 IMMUNOSUPPRESSANT DRUGS
8.4.1 RISING IMMUNOSUPPRESSANT DEMAND DRIVEN BY INCREASE IN ORGAN TRANSPLANTATION PROCEDURES
FIGURE 35 PATIENTS ON WAITING LIST VS. TRANSPLANTS PERFORMED, BY ORGAN, 2021
TABLE 41 IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
8.5 ANTIBIOTIC DRUGS
8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL DEMAND FOR ANTIBIOTIC DRUG MONITORING
TABLE 42 COMPARISON OF DIFFERENT TECHNOLOGIES FOR DETERMINING ANTIMICROBIALS LEVELS IN BIOFLUIDS
TABLE 43 ANTIBIOTIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
8.6 BRONCHODILATOR DRUGS
8.6.1 RISING PREVALENCE OF RESPIRATORY DISEASES TO ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING
TABLE 44 BRONCHODILATOR DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
8.7 PSYCHOACTIVE DRUGS
8.7.1 SURGING CASES OF MENTAL ILLNESS TO AUGMENT MARKET GROWTH
TABLE 45 PSYCHOACTIVE DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
8.8 OTHER DRUGS
TABLE 46 OTHER DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
9 THERAPEUTIC DRUG MONITORING MARKET, BY END USER
9.1 INTRODUCTION
TABLE 47 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 HOSPITAL LABORATORIES
9.2.1 HOSPITAL LABS TO DOMINATE END-USER MARKET
TABLE 48 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
9.3 COMMERCIAL & PRIVATE LABORATORIES
9.3.1 EXTENSIVE TEST MENUS OF COMMERCIAL & PRIVATE LABS TO SUSTAIN DEMAND FOR SERVICES
TABLE 49 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
9.4 OTHER END USERS
TABLE 50 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
10 THERAPEUTIC DRUG MONITORING MARKET, BY REGION
10.1 INTRODUCTION
TABLE 51 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 36 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
TABLE 52 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 54 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 55 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 56 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 57 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 58 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 59 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.2 US
10.2.2.1 Awareness regarding precision medicine to propel market
TABLE 60 NUMBER OF TESTS COVERED BY MEDICARE FOR EACH DRUG CLASS
TABLE 61 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 62 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 63 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 64 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 65 US: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 66 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Availability of funding for research to offer growth opportunities
TABLE 67 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 68 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 69 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 70 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 71 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 72 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3 EUROPE
10.3.1 EUROPE: RECESSION IMPACT
TABLE 73 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 74 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 75 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 77 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 78 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 79 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 80 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Prevalence of chronic medical conditions such as cancer and diabetes to support market growth
TABLE 81 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 82 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 83 GERMANY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 84 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 85 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 86 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.3 ITALY
10.3.3.1 Rising incidence of cancer to drive demand for TDM
TABLE 87 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
TABLE 88 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 89 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 90 ITALY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 91 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 92 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 93 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Rising awareness of benefits of TDM to accelerate demand
TABLE 94 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 95 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 96 FRANCE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 98 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 99 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Adoption of technologically advanced immunoassays to boost market
TABLE 100 SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
TABLE 101 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 102 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 103 SPAIN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 104 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 105 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 106 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.6 UK
10.3.6.1 Increasing cases of chronic diseases to support market
TABLE 107 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 108 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 109 UK: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 110 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 111 UK: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 112 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 113 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 114 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 115 ROE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 116 ROE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 117 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 118 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 37 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
TABLE 119 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 120 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 121 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 123 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 124 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY- MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 125 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 126 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Japan to dominate APAC market
TABLE 127 JAPAN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
TABLE 128 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 129 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 130 JAPAN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 131 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 132 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 133 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Rising number of organ transplants to boost market
TABLE 134 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 135 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 136 CHINA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 138 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 139 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Rising incidence of cancer to propel market
TABLE 140 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 141 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 142 INDIA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 143 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 144 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 145 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.5 ROAPAC
TABLE 146 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 147 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 148 ROAPAC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 149 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 150 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 151 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.5 REST OF THE WORLD
10.5.1 ROW: RECESSION IMPACT
TABLE 152 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 153 ROW: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 154 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 155 ROW: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 156 ROW: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 157 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
TABLE 158 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 159 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
11.3 REVENUE SHARE ANALYSIS
FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS
11.4 MARKET SHARE ANALYSIS
TABLE 160 THERAPEUTIC DRUG MONITORING MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 39 COMPANY EVALUATION QUADRANT: THERAPEUTIC DRUG MONITORING MARKET, 2021
11.6 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 40 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: THERAPEUTIC DRUG MONITORING MARKET, 2021
11.7 COMPANY FOOTPRINT ANALYSIS
TABLE 161 COMPANY FOOTPRINT
TABLE 162 COMPANY REGIONAL FOOTPRINT
TABLE 163 COMPANY PRODUCT FOOTPRINT
11.8 THERAPEUTIC DRUG MONITORING MARKET: DETAILED LIST OF KEY START-UPS/SMES
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 164 KEY PRODUCT LAUNCHES & APPROVALS
11.9.2 DEALS
TABLE 165 KEY DEALS
11.9.3 OTHER DEVELOPMENTS
TABLE 166 KEY OTHER DEVELOPMENTS
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 ABBOTT
TABLE 167 ABBOTT: BUSINESS OVERVIEW
FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2021)
12.1.2 THERMO FISHER SCIENTIFIC
TABLE 168 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 42 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
12.1.3 F. HOFFMANN-LA ROCHE
TABLE 169 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
FIGURE 43 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021)
12.1.4 SIEMENS HEALTHINEERS AG
TABLE 170 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 44 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
12.1.5 DANAHER CORPORATION
TABLE 171 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
12.1.6 BIO-RAD LABORATORIES
TABLE 172 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
FIGURE 46 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.7 BIOM?RIEUX SA
TABLE 173 BIOM?RIEUX SA: BUSINESS OVERVIEW
FIGURE 47 BIOM?RIEUX: COMPANY SNAPSHOT (2021)
12.1.8 THERADIAG
TABLE 174 THERADIAG: BUSINESS OVERVIEW
FIGURE 48 THERADIAG: COMPANY SNAPSHOT (2021)
12.1.9 GRIFOLS S.A.
TABLE 175 GRIFOLS S.A.: BUSINESS OVERVIEW
FIGURE 49 GRIFOLS S.A.: COMPANY SNAPSHOT (2021)
12.1.10 EXAGEN INC.
TABLE 176 EXAGEN INC.: BUSINESS OVERVIEW
FIGURE 50 EXAGEN INC.: COMPANY SNAPSHOT (2021)
12.1.11 ARK DIAGNOSTICS, INC.
TABLE 177 ARK DIAGNOSTICS, INC.: BUSINESS OVERVIEW
12.1.12 R-BIOPHARM AG
TABLE 178 R-BIOPHARM AG: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 APDIA GROUP
12.2.2 BIOTEZ BERLIN BUCH GMBH
12.2.3 EAGLE BIOSCIENCES, INC.
12.2.4 JASEM LABORATORY SYSTEMS AND SOLUTIONS
12.2.5 AALTO SCIENTIFIC, LTD.
12.2.6 IMMUNDIAGNOSTIK AG
12.2.7 UTAK
12.2.8 SEKISUI MEDICAL CO., LTD.
12.2.9 DIASYSTEM SCANDINAVIA AB
12.2.10 CAMBRIDGE LIFE SCIENCES LIMITED
12.2.11 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH
12.2.12 B?HLMANN LABORATORIES AG
12.2.13 SJK GLOBAL, LLC.
12.2.14 EPITOPE DIAGNOSTICS, INC.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 INSIGHTS FROM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 CUSTOMIZATION OPTIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
